ANDA Approval Receives Glenmark Pharmaceuticals for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg
Posted on June 4, 2019
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, a generic version of Aggrenox® Capsules, 25 mg/200 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.
According to IQVIATM sales data for the 12 month period ending March 2019, the Aggrenox® Capsules, 25 mg/200 mg market2 achieved annual sales of approximately $165.6 million*.
Glenmark’s current portfolio consists of 155 products authorized for distribution in the U.S. marketplace and 57 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Related Topics and Keywords
Subscribe to our FREE newsletter